Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.

[1]  H. Cushing.  The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). 1932. , 1994, Obesity research.

[2]  H. Mulder,et al.  Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. , 1994, British journal of rheumatology.

[3]  P. Meunier.  Is steroid-induced osteoporosis preventable? , 1993, The New England journal of medicine.

[4]  J. Eisman,et al.  Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. , 1993, The New England journal of medicine.

[5]  L. Bonewald,et al.  Interleukin‐1 receptor antagonist inhibits the hypercalcemia mediated by interleukin‐1 , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  R. Cowan,et al.  Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. , 1992, Thorax.

[7]  S. Silverman.  Management of corticosteroid-induced osteoporosis: A clinician's perspective , 1992, Calcified tissue international.

[8]  I. Reid,et al.  Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. , 1990, Archives of internal medicine.

[9]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[10]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[11]  L. Raisz,et al.  Glucocorticoid-induced osteoporosis: pathogenesis and management. , 1990, Annals of internal medicine.

[12]  D. Dempster.  Perspectives bone histomorphometry in glucocorticoid‐induced osteoporosis , 1989 .

[13]  I. Reid.  PATHOGENESIS AND TREATMENT OF STEROID OSTEOPOROSIS , 1989, Clinical endocrinology.

[14]  I. Reid,et al.  PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD) , 1988, The Lancet.

[15]  P. Tothill,et al.  Corticosteroids and bone mass in asthma: comparisons with rheumatoid arthritis and polymyalgia rheumatica. , 1986, British medical journal.

[16]  C. Gennari.  Glucocorticoid induced osteoporosis , 1986, Clinical endocrinology.

[17]  S. Posen,et al.  Serum osteocalcin concentrations in Paget's disease of bone. , 1986, Archives of internal medicine.

[18]  A. Adinoff,et al.  Steroid-induced fractures and bone loss in patients with asthma. , 1983, The New England journal of medicine.

[19]  D. Fink,et al.  SCREENING FOR BREAST CANCER , 1976, The Lancet.

[20]  L. Raisz,et al.  Effect of glucocorticoids on bone resorption in tissue culture. , 1972, Endocrinology.

[21]  H. Fleisch,et al.  Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo , 1969, Science.

[22]  H K Genant,et al.  Quantitative computed tomography for prediction of vertebral fracture risk. , 1985, Bone.

[23]  Avioli Lv.  Effects of chronic corticosteroid therapy on mineral metabolism and calcium absorption. , 1984 .

[24]  J. Devogelaer,et al.  The effect of low dosage glucocorticoids on bone mass in rheumatoid arthritis: a cross-sectional and a longitudinal study using single photon absorptiometry. , 1984, Advances in experimental medicine and biology.

[25]  M. Chapuy,et al.  Histomorphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis , 1979 .